Breast cancer treatment does not always end when the original tumor is removed or controlled. For some patients, cancer can return months or years later, either in the breast area or in other parts of the body.
Finding a recurrence early can be important because it may give doctors more treatment options. Researchers at Kumamoto University in Japan are studying whether a simple blood sample could provide new clues that breast cancer has returned.
The team developed an approach that examines tiny pieces of DNA circulating in the bloodstream. Their study was published in the journal Cancer Research Communications.
The research was led by Associate Professor Sugiko Watanabe and Professor Mitsuyoshi Nakao of Kumamoto University’s Institute of Molecular Embryology and Genetics. Yutaka Yamamoto of Kumamoto University Hospital and scientists from other institutions also took part.
When cells die, small pieces of their DNA can enter the blood. This material is called cell-free DNA, or cfDNA, and some of it can come from cancer cells.
Scientists have been developing blood tests known as liquid biopsies to study this DNA. Many of these tests search for mutations, which are changes in the DNA sequence that can reveal the presence or behavior of a tumor.
The Kumamoto team looked beyond mutations. They asked whether the physical way DNA is packaged inside cells could also leave useful signs in the DNA fragments found in blood.
Inside a cell, DNA is extremely long and must be carefully packed to fit inside the nucleus. It is wrapped around groups of proteins to form structures called nucleosomes, somewhat like thread wrapped around small spools.
The location of these nucleosomes is not random. Their arrangement is connected with whether nearby genes are active or inactive and how easily the cell can use different parts of its DNA.
When DNA enters the bloodstream, patterns related to this packaging can remain in the fragments. Researchers can therefore study those patterns for indirect information about what may have been happening inside the cells that released the DNA.
The study analyzed cell-free DNA from 150 breast cancer samples. Of these, 105 came from people with primary breast cancer, while 45 came from patients whose cancer had returned or spread to other parts of the body.
The researchers concentrated on 26 areas of the genome. These regions had previously been linked to changes in gene activity that occur when breast cancer cells become resistant to hormone therapy.
Hormone therapy is widely used for breast cancers that depend on hormones such as estrogen for growth. Although these treatments can work very well, some cancer cells eventually learn to survive despite the therapy, which can contribute to recurrence.
The researchers found several differences in blood DNA from recurrent cancers. These samples tended to contain more genetic variants and shorter pieces of cell-free DNA.
Two DNA regions called RERE and SYNPO2 stood out. A score based on nucleosome patterns in these regions was able to distinguish primary breast cancer samples from recurrent cancer samples with an AUC of 0.826.
An AUC is a statistical measure of how well a test separates two groups. A value of 0.5 would perform little better than chance, while a value closer to 1.0 represents stronger separation, so 0.826 was encouraging within this particular study.
The team then combined information about nucleosomes with other features of cell-free DNA. Using a computer model to analyze these signals together improved the ability to identify recurrent disease in the study data.
The findings suggest that blood DNA can provide more information than mutations alone. Its length and packaging patterns may reveal changes in how cancer cells control their genes as the disease becomes resistant to treatment or returns.
This could eventually be useful for patients who need monitoring after breast cancer treatment. A blood test is generally easier to repeat than an invasive tissue biopsy and might allow doctors to watch for molecular changes over time.
However, the new approach is not ready to replace current follow-up methods. The study was retrospective and relatively small, particularly because only 45 samples represented recurrent or metastatic cancer.
The groups also differed in breast cancer subtypes and patient characteristics. Those differences could influence the DNA patterns and make a test appear more accurate in one research group than it would be in the wider population.
Another important issue is that strong performance in an initial dataset does not guarantee that a test will work equally well in new patients. Researchers will need to test the method prospectively in larger, independent and more diverse groups.
Even with these limitations, the study is valuable because it expands the idea of what a liquid biopsy can measure. Rather than treating circulating DNA simply as a source of mutations, it uses the organization of DNA as another source of information about cancer biology.
If future studies confirm the results, nucleosome patterns could become one part of a broader blood-based system for monitoring breast cancer. The most likely value may come from combining several signals rather than relying on a single DNA marker.
Source: Kumamoto University.
